# Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

### Teduglutide (Gattex)

#### Notes:

- Quantity Limits: No
- ^Adequate trial is defined as 4 weeks treatment duration
- \*Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- \*\*Colonoscopy due within 6 months prior to starting treatment and 1 year after starting treatment. Colonoscopy due every 5 years after that (more frequent if polyps found). For pediatric patients, instead of colonoscopy, fecal occult blood testing recommended (if unexplained blood in stool, then colonoscopy/sigmoidoscopy required).

<u>Initiation (new start) criteria</u>: Non-formulary **teduglutide (Gattex)** will be covered on the prescription drug benefit for <u>6 months</u> when the following criteria are met:

- Prescriber is a Gastroenterologist
- Patient is at least 1 year old and weighs 10 kilograms or more
- Patient has a diagnosis of short bowel syndrome
- Patient is dependent on parenteral support
- Patient has had a colonoscopy in the past 6 months\*\*
- Patient has failed an adequate trial<sup>^</sup> of, or patient has an allergy or intolerance<sup>\*</sup> to, all of the following:
- At least 1 proton pump inhibitor
- Loperamide (up to 16 mg per day)
- Codeine sulfate (up to 60 mg 3 times a day)
- Octreotide (up to 300 mcg 3 times a day)

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>: Non-formulary teduglutide
(Gattex) will be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- Prescriber is a Gastroenterologist
- Patient is at least 1 year old and weighs 10 kilograms or more
- Patient has a diagnosis of short bowel syndrome
- Parenteral support need has decreased compared to baseline

<u>Continued use criteria (6 months after initiation)</u>: Non-formulary **teduglutide (Gattex)** will continue to be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- Prescriber is a Gastroenterologist
- Parenteral support need has decreased compared to baseline

kp.org

Revised: 04/11/24 Effective: 06/06/24 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



# Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE


### **Teduglutide (Gattex)**

Continued use criteria for patients previously approved per the above criteria who are currently stable on the medication: Non-formulary teduglutide (Gattex) will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescriber is a Gastroenterologist
- Parenteral support need has decreased compared to baseline
- Patient is up to date with screening colonoscopies\*\*

kp.org

Revised: 04/11/24 Effective: 06/06/24





All plans offered and underwritten by